Home Research COVID-19 Services Publications People Teaching Job Opening News Forum Lab Only
Online Services

●I-TASSER ●D-I-TASSER ●I-TASSER-MTD ●C-I-TASSER ●CR-I-TASSER ●QUARK ●C-QUARK ●D-QUARK ●DRfold ●DRfold2 ●LOMETS ●MUSTER ●CEthreader ●SEGMER ●DeepFold ●DeepFoldRNA ●FoldDesign ●COFACTOR ●COACH ●MetaGO ●TripletGO ●IonCom ●FG-MD ●ModRefiner ●REMO ●DEMO ●DEMO-EM ●DMFold ●SPRING ●COTH ●Threpp ●PEPPI ●BSpred ●ANGLOR ●EDock ●BSP-SLIM ●SAXSTER ●FUpred ●ThreaDom ●ThreaDomEx ●EvoDesign ●BindProf ●BindProfX ●SSIPe ●GPCR-I-TASSER ●MAGELLAN ●ResQ ●STRUM ●DAMpred ●TCRfinder

●TM-score ●TM-align ●US-align ●MM-align ●RNA-align ●NW-align ●LS-align ●EDTSurf ●MVP ●MVP-Fit ●SPICKER ●HAAD ●PSSpred ●3DRobot ●MR-REX ●I-TASSER-MR ●SVMSEQ ●NeBcon ●ResPRE ●TripletRes ●DeepPotential ●WDL-RF ●ATPbind ●DockRMSD ●DeepMSA ●DeepMSA2 ●FASPR ●EM-Refiner ●GPU-I-TASSER

●BioLiP ●E. coli ●GLASS ●GPCR-HGmod ●GPCR-RD ●GPCR-EXP ●Tara-3D ●TM-fold ●DECOYS ●POTENTIAL ●RW/RWplus ●EvoEF ●HPSF ●THE-DB ●ADDRESS ●Alpaca-Antibody ●CASP7 ●CASP8 ●CASP9 ●CASP10 ●CASP11 ●CASP12 ●CASP13 ●CASP14

BioLiP Library
Download all results in tab-seperated text for 59 receptor-ligand interactions, whose format is explained at readme.txt.
  • Hover over PDB to view the title of the structure. Click PDB to view the structure at the RCSB PDB database. Resolution -1.00 means the resolution is unavailable, e.g., for NMR structures.
  • Click Site # to view the binding site structure. Hover over Site # to view the binding residues.
  • Hover over Ligand to view the full ligand name. Click Ligand to view the 2D diagram and other detail information of the ligand.
  • Hover over EC number to view the full name of enzymatic activity.
  • Hover over GO terms to view all GO terms.
  • Hover over UniProt to view the protein name.

    • Sort results by
    << < 1 > >>
    Go to page

    # PDB
    (Resolution Å)     		Site # Ligand EC number GO terms UniProt PubMed Binding
    affinity
    1 6cnl:A (2.6) BS01 peptide 3.1.3.16 N/A Q96HS1 30705304
    2 6cnl:A (2.6) BS02 peptide 3.1.3.16 N/A Q96HS1 30705304
    3 6cnl:A (2.6) BS03 peptide 3.1.3.16 N/A Q96HS1 30705304
    4 6cnl:A (2.6) BS04 MG 3.1.3.16 N/A Q96HS1 30705304
    5 6cnl:B (2.6) BS01 peptide 3.1.3.16 N/A Q96HS1 30705304
    6 6cnl:B (2.6) BS02 peptide 3.1.3.16 N/A Q96HS1 30705304
    7 6cnl:B (2.6) BS03 peptide 3.1.3.16 N/A Q96HS1 30705304
    8 6cnl:B (2.6) BS04 MG 3.1.3.16 N/A Q96HS1 30705304
    9 6cnl:C (2.6) BS01 peptide 3.1.3.16 N/A Q96HS1 30705304
    10 6cnl:C (2.6) BS02 peptide 3.1.3.16 N/A Q96HS1 30705304
    11 6cnl:C (2.6) BS03 peptide 3.1.3.16 N/A Q96HS1 30705304
    12 6cnl:C (2.6) BS04 MG 3.1.3.16 N/A Q96HS1 30705304
    13 6cnl:C (2.6) BS05 MG 3.1.3.16 N/A Q96HS1 30705304
    14 6cnl:C (2.6) BS06 MG 3.1.3.16 N/A Q96HS1 30705304
    15 6cnl:C (2.6) BS07 MG 3.1.3.16 N/A Q96HS1 30705304
    16 6cnl:D (2.6) BS01 peptide 3.1.3.16 N/A Q96HS1 30705304
    17 6cnl:D (2.6) BS02 peptide 3.1.3.16 N/A Q96HS1 30705304
    18 6cnl:D (2.6) BS03 MG 3.1.3.16 N/A Q96HS1 30705304
    19 6cnl:D (2.6) BS04 MG 3.1.3.16 N/A Q96HS1 30705304
    20 6cnl:D (2.6) BS05 MG 3.1.3.16 N/A Q96HS1 30705304
    21 6cnl:E (2.6) BS01 peptide 3.1.3.16 N/A Q96HS1 30705304
    22 6cnl:E (2.6) BS02 peptide 3.1.3.16 N/A Q96HS1 30705304
    23 6cnl:E (2.6) BS03 peptide 3.1.3.16 N/A Q96HS1 30705304
    24 6cnl:E (2.6) BS04 MG 3.1.3.16 N/A Q96HS1 30705304
    25 6cnl:F (2.6) BS01 peptide 3.1.3.16 N/A Q96HS1 30705304
    26 6cnl:F (2.6) BS02 peptide 3.1.3.16 N/A Q96HS1 30705304
    27 6cnl:F (2.6) BS03 peptide 3.1.3.16 N/A Q96HS1 30705304
    28 6cnl:F (2.6) BS04 MG 3.1.3.16 N/A Q96HS1 30705304
    29 6cnl:F (2.6) BS05 MG 3.1.3.16 N/A Q96HS1 30705304
    30 6cnl:F (2.6) BS06 MG 3.1.3.16 N/A Q96HS1 30705304
    31 6cnl:F (2.6) BS07 MG 3.1.3.16 N/A Q96HS1 30705304
    32 6cnl:G (2.6) BS01 peptide 3.1.3.16 N/A Q96HS1 30705304
    33 6cnl:G (2.6) BS02 peptide 3.1.3.16 N/A Q96HS1 30705304
    34 6cnl:G (2.6) BS03 peptide 3.1.3.16 N/A Q96HS1 30705304
    35 6cnl:G (2.6) BS04 MG 3.1.3.16 N/A Q96HS1 30705304
    36 6cnl:G (2.6) BS05 MG 3.1.3.16 N/A Q96HS1 30705304
    37 6cnl:H (2.6) BS01 peptide 3.1.3.16 N/A Q96HS1 30705304
    38 6cnl:H (2.6) BS02 peptide 3.1.3.16 N/A Q96HS1 30705304
    39 6cnl:H (2.6) BS03 peptide 3.1.3.16 N/A Q96HS1 30705304
    40 6cnl:H (2.6) BS04 MG 3.1.3.16 N/A Q96HS1 30705304
    41 6cnl:I (2.6) BS01 peptide 3.1.3.16 N/A Q96HS1 30705304
    42 6cnl:I (2.6) BS02 peptide 3.1.3.16 N/A Q96HS1 30705304
    43 6cnl:I (2.6) BS03 peptide 3.1.3.16 N/A Q96HS1 30705304
    44 6cnl:I (2.6) BS04 MG 3.1.3.16 N/A Q96HS1 30705304
    45 6cnl:I (2.6) BS05 MG 3.1.3.16 N/A Q96HS1 30705304
    46 6cnl:J (2.6) BS01 peptide 3.1.3.16 N/A Q96HS1 30705304
    47 6cnl:J (2.6) BS02 peptide 3.1.3.16 N/A Q96HS1 30705304
    48 6cnl:J (2.6) BS03 peptide 3.1.3.16 N/A Q96HS1 30705304
    49 6cnl:J (2.6) BS04 MG 3.1.3.16 N/A Q96HS1 30705304
    50 6cnl:J (2.6) BS05 MG 3.1.3.16 N/A Q96HS1 30705304
    51 6cnl:K (2.6) BS01 peptide 3.1.3.16 N/A Q96HS1 30705304
    52 6cnl:K (2.6) BS02 peptide 3.1.3.16 N/A Q96HS1 30705304
    53 6cnl:K (2.6) BS03 peptide 3.1.3.16 N/A Q96HS1 30705304
    54 6cnl:K (2.6) BS04 MG 3.1.3.16 N/A Q96HS1 30705304
    55 6cnl:L (2.6) BS01 peptide 3.1.3.16 N/A Q96HS1 30705304
    56 6cnl:L (2.6) BS02 peptide 3.1.3.16 N/A Q96HS1 30705304
    57 6cnl:L (2.6) BS03 peptide 3.1.3.16 N/A Q96HS1 30705304
    58 6cnl:L (2.6) BS04 MG 3.1.3.16 N/A Q96HS1 30705304
    59 6cnl:L (2.6) BS05 MG 3.1.3.16 N/A Q96HS1 30705304
    Reference:
    • Chengxin Zhang, Xi Zhang, Peter L Freddolino, and Yang Zhang. BioLiP2: an updated structure database for biologically relevent ligand-protein interactions, Nucleic Acids Research, gkad630 (2023)(download the PDF file).
    • Jianyi Yang, Ambrish Roy, and Yang Zhang. BioLiP: a semi-manually curated database for biologically relevant ligand-protein interactions, Nucleic Acids Research, 41: D1096-D1103 (2013) (download the PDF file).

    zhanglabzhanggroup.org | +65-6601-1241 | Computing 1, 13 Computing Drive, Singapore 117417